Faculty Opinions recommendation of Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.

2006 ◽  
Author(s):  
Didier Blaise
Keyword(s):  
Cell Transplantation ◽  
Total Body Irradiation ◽  
Acute Myelogenous Leukemia ◽  
Low Dose ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Myelogenous Leukemia ◽  
Acute Myelogenous ◽  
Unrelated Donors ◽  
Total Body

Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors

2006 ◽  
Vol 24 (3) ◽  
pp. 444-453 ◽  
Author(s):  
Ute Hegenbart ◽  
Dietger Niederwieser ◽  
Brenda M. Sandmaier ◽  
Michael B. Maris ◽  
Judith A. Shizuru ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Total Body Irradiation ◽  
Low Dose ◽  
Hematopoietic Cell Transplantation ◽  
Disease Free Survival ◽  
Hematopoietic Cell ◽  
Myelogenous Leukemia ◽  
Acute Myelogenous ◽  
Unrelated Donors ◽  
Total Body

Purpose The use of low-dose, irradiation-based preparative regimens have allowed the extension of allografting to older and medically infirm patients. The study reported here assessed outcomes for patients with acute myeloid leukemia (AML) in different stages of their disease, who were not considered candidates for conventional hematopoietic cell transplantation (HCT) because of age and/or other known risk factors and were given minimal conditioning followed by HCT from related or unrelated donors. Patients and Methods The present study included 122 patients with AML, who were conditioned with 2 Gy total-body irradiation (TBI) on day 0 with or without preceding fludarabine (30 mg/m2/d from days −4 to −2), and given postgrafting cyclosporine at 6.25 mg/kg twice daily from day −3 and mycophenolate mofetil at 15 mg/kg twice daily from day 0. Results Durable engraftment was observed in 95% of the patients. Cumulative incidences of acute graft-versus-host disease grades 2 to 4 at 6 months were 35% after related and 42% after unrelated HCT, respectively. With a median follow-up of 44 months (range, 26 to 79 months), 51 patients were alive, of whom 48 were in complete remission (CR). Cumulative nonrelapse mortalities were 10% and 22%, and cumulative mortalities from disease progression were 47% and 33% at 2 years for related and unrelated recipients, respectively. Overall, 2-year survival was 48%, and disease-free survival was 44%. Patients receiving transplantation in CR1 had 2-year overall survivals of 44% after related and 63% after unrelated HCT, respectively. Conclusion We conclude that HCT from related and unrelated donors after low-dose TBI is a promising treatment for elderly patients with AML.

Sign in / Sign up

Export Citation Format

Share Document